Biosimilars Congress 2019 is included Keynote and Speakers sessions on the most recent examination intended to offer extensive worldwide exchanges that address current issues in Biosimilars Congress 2019

Developing and manufacturing biosimilars is testing, so settled biopharmaceutical organizations are putting resources into these vital medications. Europe is driving the way. The United States endorsed its fourth biosimilar in September 2016, contrasted and 15 products — marketed under 26 distinct brands — officially affirmed by the European Medicines Agency. The market will keep on developing as top rated biologics fall off patent in coming years. Many organizations worldwide are creating biosimilars to target different markets.

·         Quality by Design for Biologics and Biosimilars

·         Current concepts of drugs and Biologics

·         Cancer Therapeutics

·         Biologics in genetic disorders

·         Unique considerations for biologics and Biosimilars

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.